Conquis Financial’s AstraZeneca AZN Stock Holding History

Conquis Financial’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-97	Closed	-$12.6K	–	79
2024 Q4	$12.6K	Buy	+97	New	+$13.6K	0.01%	59

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Conquis Financial's AZN Position: Q1 2025 in Review

Conquis Financial sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 97 shares — an estimated $12.6K sold.

Conquis Financial first reported a position in AZN in Q4 2024 and held it in 1 quarter. The position peaked at $12.6K in Q4 2024. 1,249 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

Conquis Financial reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
Conquis Financial sold 97 AstraZeneca shares in Q1 2025, an estimated $12.6K.
Conquis Financial first reported a position in AstraZeneca in Q4 2024 and held it in 1 quarter.
Conquis Financial's AstraZeneca position peaked at $12.6K in Q4 2024.
1,249 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Conquis Financial's 13F filing for Q1 2025, filed 9 May 2025.